Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson's disease patients
- PMID: 28449715
- PMCID: PMC5408370
- DOI: 10.1186/s13073-017-0428-y
Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson's disease patients
Erratum in
-
Erratum to: Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson's disease patients.Genome Med. 2017 Jun 29;9(1):61. doi: 10.1186/s13073-017-0451-z. Genome Med. 2017. PMID: 28662719 Free PMC article. No abstract available.
Abstract
Background: Parkinson's disease (PD) presently is conceptualized as a protein aggregation disease in which pathology involves both the enteric and the central nervous system, possibly spreading from one to another via the vagus nerves. As gastrointestinal dysfunction often precedes or parallels motor symptoms, the enteric system with its vast diversity of microorganisms may be involved in PD pathogenesis. Alterations in the enteric microbial taxonomic level of L-DOPA-naïve PD patients might also serve as a biomarker.
Methods: We performed metagenomic shotgun analyses and compared the fecal microbiomes of 31 early stage, L-DOPA-naïve PD patients to 28 age-matched controls.
Results: We found increased Verrucomicrobiaceae (Akkermansia muciniphila) and unclassified Firmicutes, whereas Prevotellaceae (Prevotella copri) and Erysipelotrichaceae (Eubacterium biforme) were markedly lowered in PD samples. The observed differences could reliably separate PD from control with a ROC-AUC of 0.84. Functional analyses of the metagenomes revealed differences in microbiota metabolism in PD involving the ẞ-glucuronate and tryptophan metabolism. While the abundances of prophages and plasmids did not differ between PD and controls, total virus abundance was decreased in PD participants. Based on our analyses, the intake of either a MAO inhibitor, amantadine, or a dopamine agonist (which in summary relates to 90% of PD patients) had no overall influence on taxa abundance or microbial functions.
Conclusions: Our data revealed differences of colonic microbiota and of microbiota metabolism between PD patients and controls at an unprecedented detail not achievable through 16S sequencing. The findings point to a yet unappreciated aspect of PD, possibly involving the intestinal barrier function and immune function in PD patients. The influence of the parkinsonian medication should be further investigated in the future in larger cohorts.
Keywords: Archaea; Bacteria; Enteric nervous system; Gut-brain axis; Microbiome; Parkinson; Viruses.
Figures




Similar articles
-
Distinct gut microbiome characteristics and dynamics in patients with Parkinson's disease based on the presence of premotor rapid-eye movement sleep behavior disorders.Microbiome. 2025 Apr 30;13(1):108. doi: 10.1186/s40168-025-02095-w. Microbiome. 2025. PMID: 40307949 Free PMC article.
-
Gut microbiota are related to Parkinson's disease and clinical phenotype.Mov Disord. 2015 Mar;30(3):350-8. doi: 10.1002/mds.26069. Epub 2014 Dec 5. Mov Disord. 2015. PMID: 25476529
-
Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls.Parkinsonism Relat Disord. 2016 Nov;32:66-72. doi: 10.1016/j.parkreldis.2016.08.019. Epub 2016 Aug 26. Parkinsonism Relat Disord. 2016. PMID: 27591074
-
[The gut microbiome in Parkinson's disease].Nervenarzt. 2019 Feb;90(2):160-166. doi: 10.1007/s00115-018-0601-6. Nervenarzt. 2019. PMID: 30171304 Review. German.
-
Brain-gut-microbiota axis in Parkinson's disease.World J Gastroenterol. 2015 Oct 7;21(37):10609-20. doi: 10.3748/wjg.v21.i37.10609. World J Gastroenterol. 2015. PMID: 26457021 Free PMC article. Review.
Cited by
-
Protection of Fecal Microbiota Transplantation in a Mouse Model of Multiple Sclerosis.Mediators Inflamm. 2020 Aug 5;2020:2058272. doi: 10.1155/2020/2058272. eCollection 2020. Mediators Inflamm. 2020. PMID: 32831634 Free PMC article.
-
Review: The Role of Intestinal Dysbiosis in Parkinson's Disease.Front Cell Infect Microbiol. 2021 Apr 22;11:615075. doi: 10.3389/fcimb.2021.615075. eCollection 2021. Front Cell Infect Microbiol. 2021. PMID: 33968794 Free PMC article. Review.
-
Gut Microbiota and Parkinson's Disease: Implications for Faecal Microbiota Transplantation Therapy.ASN Neuro. 2021 Jan-Dec;13:17590914211016217. doi: 10.1177/17590914211016217. ASN Neuro. 2021. PMID: 34053243 Free PMC article. Review.
-
Gut microbiome and Parkinson's disease: Perspective on pathogenesis and treatment.J Adv Res. 2023 Aug;50:83-105. doi: 10.1016/j.jare.2022.10.013. Epub 2022 Nov 1. J Adv Res. 2023. PMID: 36332796 Free PMC article. Review.
-
Effect of Levodopa Initiation on the Gut Microbiota in Parkinson's Disease.Front Neurol. 2021 Mar 4;12:574529. doi: 10.3389/fneur.2021.574529. eCollection 2021. Front Neurol. 2021. PMID: 33746867 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials